Search This Blog

Monday, March 20, 2023

Gilead Exercises Option to License Nurix Protein Degrader Development Candidate

 IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement --

-- Nurix to Receive a $20 Million Option Fee --

https://finance.yahoo.com/news/gilead-exercises-option-license-nurix-123000692.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.